Ionis to get up to US$300 million from licensing deal with AstraZeneca


Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to US$300 million in milestone payments and royalties. FILE PHOTO - Traders work at the post where AstraZeneca is traded on the floor of the New York Stock Exchange in New York, U.S., October 4, 2017.



from Biotech News